Adjuvant therapy in renal cell carcinoma: the perspective of urologists.

Annabel SpekB SzabadosJ CasuscelliC StiefM Staehler

Published in: International journal of clinical oncology (2019)

A minority of urologists would use AT and are more confident in ASSURE-trial. Reluctance of prescribing AT mainly is based on lack of OS data and conflicting trial results.

Keyphrases

renal cell carcinoma
phase iii
study protocol
phase ii
clinical trial
primary care
electronic health record
randomized controlled trial
emergency department
adverse drug
deep learning